Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission file number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 58-2301143 (State or other j ...

Wall Street analysts forecast that ANI Pharmaceuticals (ANIP) will report quarterly earnings of $0.80 per share in its upcoming release, pointing to a year-over-year increase of 5.3%. It is anticipated that revenues will amount to $123.02 million, exhibiting an increase of 30.6% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 16.9% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsi ...

The market expects ANI Pharmaceuticals (ANIP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...

BAUDETTE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Leerink Partners Global Biopharma Conference in Miami Beach as follows: Date: Tuesday, March 12, 2024   Time: 2:20 p.m. ET   Webcast: Click Here    To schedule a 1x1 meeting with the Company, please contact your Leerink representative. The live and archived webcast will be ...

Group 1 - ANI Pharmaceuticals (ANIP) closed at $57.03, reflecting a +0.92% change from the previous day's close, outperforming the S&P 500's daily loss of 0.1% [1] - Over the past month, ANI Pharmaceuticals' shares have decreased by 0.41%, underperforming the Medical sector's gain of 2.32% and the S&P 500's gain of 5.78% [1] - The upcoming earnings report is scheduled for February 29, 2024, with projected EPS of $0.78, indicating a 2.63% increase year-over-year, and revenue expected to be $119.38 million, a 26.69% increase year-over-year [1] Group 2 - Recent changes to analyst estimates for ANI Pharmaceuticals reflect short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [2] - The Zacks Rank system, which assesses estimate changes, currently ranks ANI Pharmaceuticals at 3 (Hold), with the consensus EPS estimate remaining stagnant over the past month [2] - Stocks rated 1 in the Zacks Rank have historically produced an average annual return of +25% since 1988 [2] Group 3 - ANI Pharmaceuticals has a Forward P/E ratio of 13.92, which is a discount compared to the industry's average Forward P/E of 21.34 [3] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 97, placing it in the top 39% of over 250 industries [3] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [3]

BAUDETTE, Minn., Feb. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Thursday, February 29, 2024    ...

The most recent trading session ended with ANI Pharmaceuticals (ANIP) standing at $56.04, reflecting a +1.12% shift from the previouse trading day's closing. The stock's change was more than the S&P 500's daily loss of 0.32%. On the other hand, the Dow registered a loss of 0.71%, and the technology-centric Nasdaq decreased by 0.2%.Heading into today, shares of the drugmaker had lost 2.38% over the past month, lagging the Medical sector's gain of 2.33% and the S&P 500's gain of 4.59% in that time.Investors w ...

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $55.02, marking a +0.7% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.76%. Meanwhile, the Dow experienced a rise of 0.59%, and the technology-dominated Nasdaq saw an increase of 1.12%.Prior to today's trading, shares of the drugmaker had lost 0.91% over the past month. This has lagged the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5% in that time.The investment community will be ...

BAUDETTE, Minn., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York City as follows: Date: Thursday, February 8, 2024   Time: 10:30 a.m. ET   Webcast:  Click Here     To schedule a 1x1 meeting with the Company, please email: gsmanagementaccess@guggenheimpartners.com The live and archi ...

Core Viewpoint - ANI Pharmaceuticals, Inc. has launched Pentoxifylline Extended-Release (ER) Tablets, a generic version of Trental®, targeting a U.S. market valued at approximately $19.7 million annually [1][2]. Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription products, particularly for diseases with high unmet medical needs [3]. - The company aims to achieve sustainable growth by expanding its Rare Disease business and enhancing its generics business through improved research and development capabilities [3]. Product Launch - The launch of Pentoxifylline ER Tablets is part of ANI's strategy to continue momentum in its generics business within a limited competition market [2]. - The company emphasizes a patient-first approach, ensuring access to high-quality therapeutics for patients and healthcare providers [2].